Get the Stockscreener App
175.59
0.19%
0.33
After Hours:
175.65
0.06
+0.03%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $175.59, with a volume of 4.04M.
It is up +0.19% in the last 24 hours and down -0.35% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$175.26
Open:
$176.01
24h Volume:
4.04M
Relative Volume:
0.69
Market Cap:
$310.55B
Revenue:
$55.53B
Net Income/Loss:
$5.12B
P/E Ratio:
60.97
EPS:
2.88
Net Cash Flow:
$15.62B
1W Performance:
+2.88%
1M Performance:
-0.35%
6M Performance:
-5.99%
1Y Performance:
+6.47%
1-Day Range:
$173.98
$176.12
1-Week Range:
$169.25
$177.45
52-Week Range:
$153.58
$207.32
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
175.59 | 310.55B | 55.53B | 5.12B | 15.62B | 2.88 |
|
LLY
Lilly Eli Co
|
823.23 | 778.66B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.34 | 379.90B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
152.87 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
MRK
Merck Co Inc
|
98.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings? - Benzinga India
AbbVie, Exxon, Chevron, and more to report earnings Friday - Investing.com
AbbVie Q4 2024 Earnings Preview: Strong results expected on Skyrizi, Rinvoq growth trajectory - MSN
If You Invested $10,000 In AbbVie Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
OLD National Bancorp IN Sells 8,609 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
BDF Gestion Has $9.57 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
New England Research & Management Inc. Purchases 8,280 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Synergy Asset Management LLC Purchases Shares of 8,781 AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Holdings Lowered by Highland Capital Management LLC - MarketBeat
Strategic Planning Group LLC Grows Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Milestone Asset Management LLC Boosts Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Hanson & Doremus Investment Management Boosts Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Swedbank AB Reduces Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Forsta AP Fonden Buys 5,800 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Patton Fund Management Inc. Acquires New Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Hantz Financial Services Inc. Sells 1,817 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie's SWOT analysis: biopharmaceutical giant navigates post-Humira landscape - Investing.com
AbbVie (NYSE:ABBV) Shares Up 2.5%Time to Buy? - MarketBeat
AbbVie (NYSE:ABBV) Shares Up 1%Here's Why - MarketBeat
Foster Victor Wealth Advisors LLC Grows Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Is AbbVie Inc. (ABBV) the Best Stock to Buy in 2025 for Beginners? - Yahoo Finance
Asset Dedication LLC Sells 4,388 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Sumitomo Life Insurance Co. Sells 9,798 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Kennedy Investment Group Boosts Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Orca Wealth Management LLC Takes $1.86 Million Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Acquired by BSW Wealth Partners - MarketBeat
YHB Investment Advisors Inc. Buys 3,352 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Perigon Wealth Management LLC Buys 17,432 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans - PR Newswire
AbbVie (ABBV) to Release Quarterly Earnings on Friday - MarketBeat
Pancreatic Cancer Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma - Barchart
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
A Glimpse Into The Expert Outlook On AbbVie Through 15 Analysts - Benzinga
AbbVie (NYSE:ABBV) Trading Down 0.1% Following Analyst Downgrade - MarketBeat
AbbVie (NYSE:ABBV) Price Target Lowered to $205.00 at Citigroup - MarketBeat
AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results? - Yahoo Finance
BankPlus Wealth Management LLC Makes New Investment in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Citigroup Adjusts Price Target on AbbVie to $205 From $215, Maintains Buy Rating -January 28, 2025 at 06:48 am EST - Marketscreener.com
Court Place Advisors LLC Cuts Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Nilsine Partners LLC Has $1.71 Million Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One. - The Motley Fool
AbbVie Inc. (NYSE:ABBV) Shares Sold by Pacer Advisors Inc. - MarketBeat
Foundations Investment Advisors LLC Sells 44,138 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Baldwin Wealth Partners LLC MA Lowers Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Mount Yale Investment Advisors LLC Acquires 1,514 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Navigating Market Uncertainty: Intrinsic Value of AbbVie Inc - Yahoo Finance
Summit Financial Strategies Inc. Purchases 4,441 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Webster Bank N. A. Cuts Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Kingswood Wealth Advisors LLC Has $2.19 Million Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still Bearish - MSN
AbbVie's SWOT analysis: biopharma giant navigates post-Humira landscape - MSN
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):